Atavistik Bio, which is developing treatments for blood cancer and bleeding disorders, raised $40 million in Series B extension financing, bringing the round to $160 million.
What's next: The funds will support achieving clinical proof of concept for its two lead programs, CEO Bryan Stuart tells Axios Pro.
